Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.60
+5.33 (2.41%)
AAPL  272.18
+0.34 (0.13%)
AMD  202.62
+4.51 (2.28%)
BAC  54.18
-0.37 (-0.68%)
GOOG  304.35
+6.29 (2.11%)
META  666.00
+16.50 (2.54%)
MSFT  486.60
+10.48 (2.20%)
NVDA  175.13
+4.19 (2.45%)
ORCL  179.69
+1.22 (0.69%)
TSLA  488.21
+20.95 (4.48%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.